Needle and Non-Needle Acupuncture in Migraine Treatment

Chronic Migraine Treatment Tied to Nickel Allergy

Skin & Allergy News ◽

10.1016/s0037-6337(06)71410-3 ◽

2006 ◽

Vol 37 (7) ◽

pp. 62

Author(s):

BRUCE JANCIN

Keyword(s):

Chronic Migraine ◽

Migraine Treatment ◽

Nickel Allergy

Download Full-text

Formulation and Evaluation of Fish Oil-based Rizatriptan Microemulsion for Intranasal Migraine Treatment

International Journal of Pharmaceutical Sciences and Nanotechnology ◽

10.37285/ijpsn.2015.8.3.12 ◽

2015 ◽

Vol 8 (3) ◽

pp. 2972-2978

Author(s):

Kanchan P Upadhye ◽

Divya Senpal ◽

Minakshee Nimbalwar ◽

Gouri Dixit

Keyword(s):

Fish Oil ◽

Nasal Cavity ◽

Residence Time ◽

Stability Study ◽

Migraine Treatment ◽

Existence Region ◽

Microemulsion Based Gel ◽

Micro Emulsion ◽

Pseudoternary Phase Diagram

In the present study microemulsion based intranasal gel of rizatriptan using fish oil was prepared for treatment and management of migraine to sustain the drug release and improve the drug residence time in nasal cavity. Fish oil is reported to have antimigraine activity hence it has been used in the present formulation along with cremophore EL as surfactant and Transcutol P as co-surfactant. The pseudoternary phase diagram plotted with these components shown the microemulsion existence region in ratio of (1:9-9:1) surfactant and co-surfactant. The optimized micro-emulsion contained fish oil (45.29%), cremophore E/transcutol P (2:1) and was characterized for pH (6.3±0.02), viscosity (114 ± 3.00cp), % transmittance (99.5 ± 1.01), refractive index (1.335±0.01),). The prepared microemulsion gels were optimized and characterized for in-vitro studies, pH, drug content, rheological studies and stability study. The release of rizatriptan from micro-emulsion gel prepared from carbopol 934 (98.01%) was found to be higher and prolonged than plain gel. Thus, microemulsion based gel was able to prolong drug releaseand improve drug residence time in the nasal cavity.

Download Full-text

Migraine treatment and COVID‐19 vaccines: No cause for concern

Headache The Journal of Head and Face Pain ◽

10.1111/head.14086 ◽

2021 ◽

Vol 61 (3) ◽

pp. 409-411

Author(s):

Amy A. Gelfand ◽

Gregory Poland

Keyword(s):

Migraine Treatment

Download Full-text

CGRP-Receptor Antagonism in Migraine Treatment

CNS & Neurological Disorders - Drug Targets ◽

10.2174/187152707781387314 ◽

2007 ◽

Vol 6 (4) ◽

pp. 240-246 ◽

Cited By ~ 19

Author(s):

Lars Edvinsson ◽

Kenneth Ahrend Petersen

Keyword(s):

Migraine Treatment ◽

Cgrp Receptor ◽

Receptor Antagonism

Download Full-text

Triptan use after starting prophylactic migraine treatment: A retrospective cohort study in a primary care population

Cephalalgia ◽

10.1177/0333102414521511 ◽

2014 ◽

Vol 34 (11) ◽

pp. 927-932 ◽

Cited By ~ 2

Author(s):

Antonia FH Smelt ◽

Willem JJ Assendelft ◽

Christel E van Dijk ◽

Jeanet W Blom

Keyword(s):

Primary Care ◽

Clinical Trials ◽

Cohort Study ◽

Retrospective Cohort ◽

Daily Practice ◽

Rank Test ◽

Migraine Treatment ◽

Prophylactic Effect ◽

Primary Care Population ◽

Wilcoxon Rank Test

Background Clinical trials on the prophylactic effect of propranolol and metoprolol for migraine show that starting this medication leads to a decrease in the use of attack medication of 0.9–8.9 doses per month. However, studies in daily practice are lacking. Methods We compared the number of triptans prescribed in the six months before and the six months after the start of propranolol/metoprolol in a Dutch national representative primary care cohort. Results Of the 168 triptan-using patients who started with propranolol or metoprolol, the number of triptans prescribed before starting was 4.6 doses per month. The number of triptans prescribed six months before compared with six months after starting propranolol/metoprolol decreased with 1.0 dose per month (Wilcoxon rank test; p = 0.000). Conclusion In this primary care population, although the number of triptans prescribed decreased after starting propranolol or metoprolol, the decrease is relatively small compared to data from clinical trials.

Download Full-text